title: (99M)Technetium-sestamibi scintimammography in non-palpable breast lesions found on screening X-ray mammography.
abstract: OBJECTIVE
  The sensitivity and specificity of (99m)Tc-sestamibi scintimammography in patients with non-palpable breast lesions diagnosed by screening mammography and the value of (99m)Tc-sestamibi to detect axillary lymph node metastases was determined.
  
  
  METHODS
  Between September 2000 and December 2003, 103 females with non-palpable breast lesions were included for further evaluation. X-ray mammography was repeated and 99mTc-sestamibi scintimammography performed within one-week. Anterior, and left and right lateral images were obtained. The scintimammography was analysed by 2 experienced observers who were blinded to the clinical, pathological, and radiological results. The sensitivity and specificity of scintimammography to diagnose non-palpable lesion(s), including the axillary regions, was compared with histopathology, clinical, and radiological follow up.
  
  
  RESULTS
  Two patients (one non-small lung cancer and one non-Hodgkin's disease) were excluded. Both showed (99m)Tc-sestamibi avid lesions in the breast and axillary region. In the remaining 101 patients, 37 true positive (TP), 4 false positive (FP), 52 true negative (TN), and 8 false negative (FN) breast carcinomas were found. The specificity was 92.8%, sensitivity 82.2%, positive predictive value (PPV) 90.2%, and negative predictive value (NPV) 86.6%. (99m)Tc-sestamibi scintimammography showed axillary lesions in 5/15 (33%) patients with axillary lymph node metastasis.
  
  
  CONCLUSIONS
  In patients with non-palpable lesions diagnosed by screening- X-ray-mammography, (99m)Tc-sestamibi scintimammography provided high specificity and PPV. Furthermore, (99m)Tc-sestamibi scintimammography detected 33% of patients with axillary lymph node metastases. Therefore, (99m)Tc-sestamibi scintimammography could be of incremental value in the surgical work-up of these patients.
authors.affiliation: Department of Nuclear Medicine, Westfries Hospital Hoorn, PO BOX 600, 1620 AR Hoorn, The Netherlands. g.m.m.gommans@mca.nl
authors.forename: G M M
authors.initials: GM
authors.lastname: Gommans
authors.forename: F M
authors.initials: FM
authors.lastname: van der Zant
authors.forename: A
authors.initials: A
authors.lastname: van Dongen
authors.forename: R O
authors.initials: RO
authors.lastname: Boer
authors.forename: G J J
authors.initials: GJ
authors.lastname: Teule
authors.forename: J W D
authors.initials: JW
authors.lastname: de Waard
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000000981:diagnostic imaging* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000000981:diagnostic imaging* / Q000473:pathology; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008327:Mammography / Q000379:methods*; D008875:Middle Aged; D010173:Palpation; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D017256:Technetium Tc 99m Sestamibi / Q000008:administration & dosage
chemical_list: D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi